ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,781Medicare Part D Prescriptions Filled, Including Refills

Rank: 20 out of 103

$586K Total Retail Price of All Prescriptions

Rank: 17 out of 103

481 Patients Receiving at Least One Drug in Part D
99%Patients 65 Years and Older
25% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 481 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

12% of this provider’s 481 patients filled at least one prescription for a schedule three drug, compared to an average of 20%.

Risky Drugs to Seniors

1% of this provider’s 9,675 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
LEVOTHYROXINE SODIUM 449 438 1 4
SIMVASTATIN 435 435 2 1
LISINOPRIL 339 339 3 2
POTASSIUM CHLORIDE 300 300 4 12
AMLODIPINE BESYLATE 282 282 5 5
FUROSEMIDE 269 269 6 6
OMEPRAZOLE 261 250 7 7
ATENOLOL 250 250 8 19
HYDROCHLOROTHIAZIDE 235 234 9 15
HYDROCODONE-ACETAMINOPHEN 231 221 S3 10 3
WARFARIN SODIUM 208 208 11 9
METOPROLOL TARTRATE 205 205 12 8
TRAMADOL HCL 169 169 13 20
DONEPEZIL HCL 163 163 14 11
ALENDRONATE SODIUM 145 141 15 25
PRAVASTATIN SODIUM 143 143 16 27
LANTUS 137 137 17 29
CITALOPRAM HBR 130 130 18 10
LOVASTATIN 114 114 19 55
ISOSORBIDE MONONITRATE ER 106 106 20 26
LOSARTAN POTASSIUM 104 104 21 23
SERTRALINE HCL 103 93 22 18
MIRTAZAPINE 102 102 23 24
METOPROLOL SUCCINATE 101 101 24 17
LORAZEPAM 98 89 25 182
NAMENDA 90 90 26 16
PRAMIPEXOLE DIHYDROCHLORIDE 84 84 27 139
KLOR-CON 10 83 83 28 150
ALLOPURINOL 83 83 28 36
AGGRENOX 80 80 30 157
CARVEDILOL 78 78 31 22
ATORVASTATIN CALCIUM 78 78 31 21
DIGOXIN 72 72 33 49
METFORMIN HCL 71 71 34 14
SPIRONOLACTONE 71 71 34 71
TRAZODONE HCL 70 70 36 39
DIOVAN 64 64 37 72
BUMETANIDE 63 63 38 54
CLOPIDOGREL 59 59 39 28
CRESTOR 55 55 40 66
JANTOVEN 54 54 41 96
INSULIN SYRINGE 53 53 42 97
PANTOPRAZOLE SODIUM 52 52 43 37
CYMBALTA 52 43 43 56
FENTANYL 52 52 S2 43 48
SPIRIVA 50 50 46 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 11, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.